Key result
Inhibition of MMP2/9 with SB-3CT reversed diastolic dysfunction, endothelial glycocalyx thinning, and albumin extravasation in a mouse model of diabetic cardiomyopathy.
Why the study?
MMP2 and 9 degrade endothelial glycocalyx components and are upregulated in diabetes, but whether their inhibition protects endothelial glycocalyx and improves diastolic function was unproven.
Does MMP2/9 inhibition improve diastolic function and protect the endothelial glycocalyx in a mouse model of diabetic cardiomyopathy?
Does MMP2/9 inhibition improve diastolic function and protect the endothelial glycocalyx in a mouse model of diabetic cardiomyopathy?
Inhibition of MMP2/9 protects the coronary microvascular endothelial glycocalyx and improves diastolic function in a mouse model of diabetic cardiomyopathy, suggesting a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Offers preclinical support for MMP2/9 inhibition in diabetic cardiomyopathy; leaves open clinical translation.
The coronary microvascular endothelial glycocalyx (EGlx) is a vital regulator of vascular permeability and EGlx damage contributes to the development of diabetic cardiomyopathy. Matrix metalloproteinases 2 and 9 (MMP2/9) have been identified as key enzymes in the degradation of EGlx components, notably syndecan 4 (SDC4), and are upregulated in diabetes. We tested the hypothesis that inhibition of MMP2/9 can protect the EGlx and improve diastolic function in diabetic cardiomyopathy. Type 1 diabetes was induced in FVB mice by streptozotocin (STZ) injections. Mice were treated with daily injections of the MMP2/9 inhibitor, SB-3CT, for 2 weeks from 7 weeks post STZ. Echocardiography was utilised to assess heart function and lectin staining for the measurement of EGlx depth. Immunolabelling of heart sections for albumin provided an indication of albumin extravasation. A mechanism of EGlx shedding was investigated in vitro in human coronary microvascular endothelial cells treated with TNF-α and SB-3CT. Diabetic mice developed diastolic dysfunction from 6 weeks post STZ. MMP2/9 inhibition reversed diastolic dysfunction, EGlx thinning and albumin extravasation in diabetic animals. In vitro, TNF-α caused an increase in MMP9 activity and SDC4 shedding from human coronary microvascular endothelial cells. Treatment with SB-3CT reduced MMP9 activity and prevented SDC4 shedding. Knockdown of MMP9 expression prevented TNF-α induced SDC4 shedding. This study demonstrates MMP2/9 inhibition as a strategy to protect the EGlx and improve diastolic function in diabetic cardiomyopathy. Our findings suggest new avenues for therapeutic interventions in cardiovascular complications associated with diabetes. Statements and Declarations Competing interests The authors have no competing interests to declare that are relevant to the content of this article.
No takes yet. Share an insight, caveat, or question.
Buffonge et al. (2023) studied Diabetic Cardiomyopathy. SB-3CT (MMP2/9 inhibitor) vs. Vehicle was evaluated on Diastolic function (E/A ratio) and endothelial glycocalyx depth (p=<0.01). Inhibition of MMP2/9 with SB-3CT reversed diastolic dysfunction, endothelial glycocalyx thinning, and albumin extravasation in a mouse model of diabetic cardiomyopathy.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: